UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 115

Sortiert nach

Socio-economic differences in psychiatric in-patient care

Acta psychiatrica Scandinavica, 2003-03, Vol.107 (3), p.170-177

2003

Volltextzugriff (PDF)

Costs induced by hip fractures: A prospective controlled study in Belgium

Osteoporosis international, 2000-05, Vol.11 (5), p.373-380

2000

Volltextzugriff (PDF)

Deriving a risk-adjustment formula for hospital financing: Integrating the impact of socio-economic status on length of stay

Social science & medicine (1982), 2008-01, Vol.66 (1), p.88-98

2008

Volltextzugriff (PDF)

Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model

Atherosclerosis, 1998-04, Vol.137, p.S111-S116

1998

Volltextzugriff (PDF)

Comparison of Drugs Use According to Surgical Procedures as Instrument for Budgeting and Improvement of Prescription Efficiency

Acta chirurgica Belgica, 1999-08, Vol.99 (4), p.195-200

Closon, M. C.

1999

Volltextzugriff (PDF)

Hospital response to prospective financing of in-patient days: The Belgian case

Health policy (Amsterdam), 2007-12, Vol.84 (2), p.200-209

2007

Volltextzugriff (PDF)

Differences in nurse (aid) staffing in acute geriatric departments in general hospitals in Europe

European geriatric medicine, 2010-10, Vol.1 (5), p.320-322

2010

Volltextzugriff (PDF)

Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium

Acta cardiologica, 2000-08, Vol.55 (4), p.239-246

2000

Volltextzugriff (PDF)

Drug use in relation to clinical activities as an instrument for prospective drug budgeting. The Belgian experience

PharmacoEconomics, 1996-03, Vol.9 (3), p.246-263

1996

Volltextzugriff (PDF)

Case-based telematic systems towards equity in health care in Belgium

Studies in health technology and informatics, 1994, Vol.14, p.160

1994

Volltextzugriff (PDF)

Trends in the utilization of DRGs in Belgium

Sozial- und Präventivmedizin, 1989-01, Vol.34 (4), p.167-174

Closon, M C

1989

Volltextzugriff (PDF)

MC4 COMPARISON OFTHREE INSTRUMENTS ASSESSING THE QUALITY OF ECONOMIC EVALUATIONS

Value in health, 2007, Vol.10 (6), p.A224-A225

2007

Volltextzugriff (PDF)

Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group

Osteoporosis international, 2000, Vol.11 (5), p.373-380

2000

Volltextzugriff (PDF)

Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study

Acta cardiologica, 2000-08, Vol.55 (4), p.239-246

2000

Volltextzugriff (PDF)

TPE5: COST OF MANAGING BENIGN PROSTATE HYPERPLASIA IN BELGIUM

Value in health, 1999-09, Vol.2 (5), p.376-376

1999

Volltextzugriff (PDF)

PP27. Cost minimization analysis of treatment of T1N0 glottic squamous cell carcinomas: Comparison between radiotherapy, laser microsurgery and partial laryngectomy

European journal of cancer (1990), 1997-11, Vol.33, p.S24-S24

1997

Volltextzugriff (PDF)

CVB3 Evaluation of the Costs of Coronary Heart Disease in Belgium

Value in health, 1998-05, Vol.1 (1), p.33-33

1998

Volltextzugriff (PDF)

PCV19 Evaluation of the Costs of Heart Failure in Belgium

Value in health, 1998-05, Vol.1 (1), p.55-56

1998

Volltextzugriff (PDF)

Trends in the utilization of DRGs in Belgium

Sozial- und Präventivmedizin, 1989, Vol.34 (4), p.167

Closon, M C

1989

Volltextzugriff (PDF)

Hospital comparisons using a Euro Health Data Base for resource management and strategic planning

Health policy (Amsterdam), 1991-03, Vol.17 (2), p.165-177

1991

Volltextzugriff (PDF)

Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer

Journal of clinical oncology, 2001-06, Vol.19 (12), p.3103-3110

2001

Volltextzugriff (PDF)

Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children

Clinical pharmacology and therapeutics, 2013-08, Vol.94 (2), p.243-251

2013

Volltextzugriff (PDF)

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children

Pediatric blood & cancer, 2013-08, Vol.60 (8), p.1375-1381

2013

Volltextzugriff (PDF)

HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

Annals of oncology, 2001-08, Vol.12 (8), p.1081-1089

2001

Volltextzugriff (PDF)

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent

The pharmacogenomics journal, 2014-04, Vol.14 (2), p.160-170

2014

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Französisch
(79)
Englisch
(36)

Erscheinungsjahr

n.n

Thema

Humans
(54)
Female
(31)
Old Medline
(27)
Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Male
(18)
Middle Aged
(15)
Belgium
(14)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Adult
(13)
Aged
(11)
Animals
(9)
Child
(8)
Child, Preschool
(8)
Infant
(8)
Adolescent
(7)
Pharmacology. Drug Treatments
(7)
Rats
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Socio-economic differences in psychiatric in-patient care

Costs induced by hip fractures: A prospective controlled study in Belgium

Deriving a risk-adjustment formula for hospital financing: Integrating the impact of socio-economic status on length of stay

Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model

Comparison of Drugs Use According to Surgical Procedures as Instrument for Budgeting and Improvement of Prescription Efficiency

Hospital response to prospective financing of in-patient days: The Belgian case

Differences in nurse (aid) staffing in acute geriatric departments in general hospitals in Europe

Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium

Drug use in relation to clinical activities as an instrument for prospective drug budgeting. The Belgian experience

Case-based telematic systems towards equity in health care in Belgium

Trends in the utilization of DRGs in Belgium

MC4 COMPARISON OFTHREE INSTRUMENTS ASSESSING THE QUALITY OF ECONOMIC EVALUATIONS

Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group

Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study

TPE5: COST OF MANAGING BENIGN PROSTATE HYPERPLASIA IN BELGIUM

PP27. Cost minimization analysis of treatment of T1N0 glottic squamous cell carcinomas: Comparison between radiotherapy, laser microsurgery and partial laryngectomy

CVB3 Evaluation of the Costs of Coronary Heart Disease in Belgium

PCV19 Evaluation of the Costs of Heart Failure in Belgium

Trends in the utilization of DRGs in Belgium

Hospital comparisons using a Euro Health Data Base for resource management and strategic planning

Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer

Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children

HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent

Suchergebnisse filtern